Indian Journal of Pharmaceutical Education and Research logo

Indian Journal of Pharmaceutical Education and Research

Volume 56, Issue 2s (Supplement)

2022 · pp. S121–S373 · 25 articles

Volume
56
Issue
2s
Published
2022
Pages
S121–S373
Articles
25
Sections
2
ISSN
0019-5464
Journal
IJPER

In this issue

21–25 of 25

Original Article(continued)

  1. Anjna Rani, Sunil Kumar, Roop K Khar

    pp. S326-S338 · DOI: 10.5530/ijper.56.2s.103 · 2022

    Background: Phytosome is a novel technique introduced by Indena that combines standardised herbal extract and phospholipid in preferably equal ratio to provide better absorption enhancing bioavailability. Purpose: The ob…

  2. Prem Prakash Singh, Srividya Gorantla, Ranendra N Saha, Gautam Singhvi

    pp. S339-S346 · DOI: 10.5530/ijper.56.2s.104 · 2022

    Background: The objective of this work is to develop and validate a reverse-phase HPLC method for determining Loteprednol Etabonate in self micro emulsifying drug delivery systems at nanogram level. Methods: A systematic…

  3. Murthannagari Vivek Reddy, Gonna Nandhi Krishnan Ganesh, Syed Suhaib Ahmed, Praharsh Kumar Mandadhi Rajendra, Eknath Babu

    pp. S347-S355 · DOI: 10.5530/ijper.56.2s.105 · 2022

    Introduction: Generic drug approval before patent expiration involves patent infringement petitions due to robust Life Cycle Management (LCM) strategies followed by Branded companies. They will extend the patent period o…

  4. Dilip Chandrasekhar, Mohammed Salim Karattuthodi, Linu Mohan Panakkal, Angel Mary William, Anjana A, Annmaria Benny, Aqila Karuppam, Beneta Sarah Sam, Shinu Cholamugath, Jaffer Chalil Parambil, Aneesh Puthiyedath Joy

    pp. S356-S364 · DOI: 10.5530/ijper.56.2s.106 · 2022

    Introduction: The meteoric spread of COVID-19 had facilitated the researchers to develop vaccines. One among the most recommended, Covishield requires further investigations for lighting up the society towards the immuni…

  5. Nitin Shirsath, Dipak Marathe, Priyanka Jaiswal, Laxmikant Zawar

    pp. S365-S373 · DOI: 10.5530/ijper.56.2s.107 · 2022

    Background: Azilsartan medoxomil (AZL) is an orally active nonpeptide angiotensin II receptor antagonist with less water solubility and oral bioavailability. Objectives: Increase the solubility and dissolving rate of AZL…